LANADELUMAB (Takhyzro®)

Clinical Indication

Preventing recurrent attacks of hereditary angioedema

Comments

In line with NICE TA606

Date of classification

January 2020

Review date

January 2020

Red

Drugs which should be prescribed only by hospital specialists (clinical review by specialist as appropriate and annually as a minimum).